Autor: |
Bahar Zivak, Dominique S. Meyer, John T. Li, Rosemary J. Akhurst, Nilgun Isik Reed, Eswari Dodagatta-Marri, Mark B. Headley, Anand Giddabasappa, Kai-Hui Sun, Niessen Kyle Steven, Bing Yang, Sharon Yang, Joselyn S. Del Cid, Dean Sheppard, Maeva Adoumie, Michael Rosenblum, Tatsuya Tsukui, Hsiao-Yen Ma, Amha Atakilit, Xin Ren, Kavon Noorbehesht, Joseph Dal Porto, Byron Hann, Benjia Liang, Lauren Pinzas |
Rok vydání: |
2020 |
Předmět: |
|
Zdroj: |
SSRN Electronic Journal. |
ISSN: |
1556-5068 |
DOI: |
10.2139/ssrn.3588885 |
Popis: |
The αvβ8 integrin is a key activator of transforming growth factor β(TGFβ), which has been shown to inhibit anti-tumor immunity. Previous work has suggested that αvβ8 on tumor cells could modulate tumor growth and responses to immune checkpoint blockade. We now show that a potent blocking monoclonal antibody against avb8 (ADWA-11) causes growth suppression or complete regression in syngeneic models of squamous cell carcinoma (CCK168), mammary cancer (EMT-6), colon cancer (CT26), and prostate cancer (TRAMPC2), especially when it is combined with other immunomodulators (anti-PD-1, anti-CTLA-4 or 4-1BB) or radiotherapy. αvβ8 is expressed on tumor cells in some of these models, but tumor cell expression of avb8 is not essential for the beneficial effects of ADWA-11 therapy. αvβ8 is consistently expressed at highest levels on CD4+CD25+ T cells within tumors, and specific deletion of Itgb8 from T cells is as effective as ADWA-11 in suppressing tumor growth. Treatment with ADWA-11 increases expression of a suite of genes in tumor infiltrating CD8+ T cells that are normally inhibited by TGFβ and are involved in tumor cell killing, including Granzyme B and Interferon-g. These findings solidify αvβ8 integrin as a promising target for cancer immunotherapy, even for tumors that do not express this integrin. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|